213 related articles for article (PubMed ID: 17087304)
21. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
[TBL] [Abstract][Full Text] [Related]
22. [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Kawamori R; Kadowaki T; Ishida H
Nihon Rinsho; 2004 Apr; 62(4):831-9. PubMed ID: 15106356
[No Abstract] [Full Text] [Related]
23. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Pratley RE; Foley JE; Dunning BE
Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
[TBL] [Abstract][Full Text] [Related]
24. [NAVIGATOR trial (nateglinide)].
Tsujii S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():483-7. PubMed ID: 15779426
[No Abstract] [Full Text] [Related]
25. Pharmacogenomics of glinides.
Chen M; Hu C; Jia W
Pharmacogenomics; 2015 Jan; 16(1):45-60. PubMed ID: 25560470
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
27. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
[TBL] [Abstract][Full Text] [Related]
28. Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
Sevinc A
Arch Intern Med; 2003 Jul; 163(14):1741. PubMed ID: 12885691
[No Abstract] [Full Text] [Related]
29. [Sulfonylureas and glinides].
Hirose T
Nihon Rinsho; 2006 Dec; 64 Suppl 9():646-53. PubMed ID: 17458297
[No Abstract] [Full Text] [Related]
30. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
31. [Sulfonylureas and glinides].
Kudo K; Hirose T
Nihon Rinsho; 2011 Jan; 69 Suppl 1():645-53. PubMed ID: 21766676
[No Abstract] [Full Text] [Related]
32. [Non-SU, insulin secretagogues].
Kikuchi M
Nihon Rinsho; 1999 Mar; 57(3):702-8. PubMed ID: 10199157
[TBL] [Abstract][Full Text] [Related]
33. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
34. Panel discussion on achieving glycemic control.
Buse JB; Einhorn D
Postgrad Med; 2001 Dec; 110(6 Suppl):20-5. PubMed ID: 19667581
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacological treatment of postprandial hyperglycemia].
Blickle JF
Diabetes Metab; 2000 Jun; 26 Suppl 2():20-4. PubMed ID: 10975046
[TBL] [Abstract][Full Text] [Related]
36. Postprandial hyperglycemia as an etiological factor in vascular failure.
Node K; Inoue T
Cardiovasc Diabetol; 2009 Apr; 8():23. PubMed ID: 19402896
[TBL] [Abstract][Full Text] [Related]
37. [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Tamura H; Mokuno H; Daita H
Nihon Rinsho; 2006 Nov; 64(11):2119-25. PubMed ID: 17087306
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance, pathogenesis, and management of postprandial hyperglycemia.
Gerich JE
Arch Intern Med; 2003 Jun; 163(11):1306-16. PubMed ID: 12796066
[TBL] [Abstract][Full Text] [Related]
39. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
40. Multifactorial aspects of the treatment of the type II diabetic patient.
Colwell JA
Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
